Covid-19 roundup: Mod­er­na sends in EUA for bi­va­lent teen boost­er; US trim­ming Pfiz­er/BioN­Tech do­na­tions

Though Mod­er­na’s bi­va­lent vac­cine to counter the Omi­cron vari­ant has cleared the ini­tial hur­dles in get­ting FDA au­tho­riza­tion, the vac­cine mak­er is mov­ing on to the next step.

On Twit­ter, the com­pa­ny an­nounced on Fri­day that it has filed a EUA for its bi­va­lent vac­cine for use in ado­les­cents aged 12 through 17 and for small­er chil­dren aged six through 11.

We have sub­mit­ted a re­quest for emer­gency use au­tho­riza­tion (EUA) for our Omi­cron-tar­get­ing bi­va­lent #COVID19 #vac­cine, mR­NA-1273.222, in chil­dren and ado­les­cents 12 to 17 years of age to the U.S. FDA. The EUA sub­mis­sion for chil­dren ages 6 to 11 years old was al­so com­plet­ed. pic.twit­ter.com/8cj659zOU1

— Mod­er­na (@mod­er­na_tx) Sep­tem­ber 23, 2022

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER